Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer

Urology

Volumn 68, Issue 6, 2006, Pages 1188-1192

  Tsai, Henry K ^a   Katz, Matthew S ^a   Coen, John J ^a   Zietman, Anthony L ^a   Kaufman, Donald S ^a   Shipley, William U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYSTECTOMY; DATA ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HYDRONEPHROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; CYSTOSCOPY; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33845345959     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.08.1078     Document Type: Article

References (25)

1. Shipley W.U., Prout Jr. G.R., Einstein A.B., et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258 (1987) 931-935
2. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60 (2002) 62-67
3. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20 (2002) 3061-3071
4. Shipley W.U., Kaufman D.S., Tester W.J., et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 97 (2003) 2115-2119
5. FitzGerald T.J., Daugherty C., Kase K., et al. Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate: implications for increased therapeutic ratio of low dose rate irradiation. Am J Clin Oncol 8 (1985) 517-522
6. Sklar M.D. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239 (1988) 645-647
7. Bernhard E.J., Stanbridge E.J., Gupta S., et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 60 (2000) 6597-6600
8. McKenna W.G., Muschel R.J., Gupta A.K., et al. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22 (2003) 5866-5875
9. Miller A.C., Kariko K., Myers C.E., et al. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 53 (1993) 302-307
10. Graaf M.R., Richel D.J., van Noorden C.J., et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30 (2004) 609-641
11. Katz M.S. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2 (2005) 82-89
12. Sleijfer S., van der Gaast A., Planting A.S., et al. The potential of statins as part of anti-cancer treatment. Eur J Cancer 41 (2005) 516-522
13. Stamm J.A., and Ornstein D.L. The role of statins in cancer prevention and treatment. Oncology 19 (2005) 739-750
14. Jakobisiak M., Bruno S., Skierski J.S., et al. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88 (1991) 3628-3632
15. Kamat A.M., and Nelkin G.M. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66 (2005) 1209-1212
16. Thibault A., Samid D., Tompkins A.C., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 (1996) 483-491
17. Kim W.S., Kim M.M., Choi H.J., et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19 (2001) 81-83
18. Kawata S., Yamasaki E., Nagase T., et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer 84 (2001) 886-891
19. Katz M.S., Zelefsky M.J., Marion C., et al. Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer. (abstract). Int J Radiat Oncol Biol Phys 57 (2003) S271
20. Katz M.S., Minsky B.D., Saltz L.B., et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62 (2005) 1363-1370
21. Moyad M.A., Merrick G.S., Butler W.M., et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66 (2005) 1150-1154
22. Winquist E., Moore M.J., Chi K.N., et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 23 (2005) 143-149
23. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
24. Aznar S., Fernandez-Valeron P., Espina C., et al. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett 206 (2004) 181-191
25. Miller G.E., and Stagnitti M.N. Trends in Statin Use in the Civilian Noninstitutionalized Medicare Population, 1997 and 2002 (2005), Agency for Healthcare Research and Quality, Rockville, MD. http://www.meps.ahrq.gov/papers/st97/stat97.pdf http://www.meps.ahrq.gov/papers/st97/stat97.pdf. Accessed January 27, 2006.